Innovent Biologics (IVBXF)
OTHER OTC:IVBXF
Holding IVBXF?
Track your performance easily

Innovent Biologics (IVBXF) Financial Statements

32 Followers

Innovent Biologics Financial Overview

Innovent Biologics's market cap is currently ―. The company's EPS TTM is $-0.112; its P/E ratio is -40.86; Innovent Biologics is scheduled to report earnings on March 26, 2025, and the estimated EPS forecast is $-0.03. See an overview of income statement, balance sheet, and cash flow financials.
Jun 22Dec 21Jun 21Dec 20Jun 20
Income Statement-
Total Revenue-----
Gross Profit-----
EBIT-----
EBITDA-----
Net Income Common Stockholders-----
Balance Sheet-
Cash, Cash Equivalents and Short-Term Investments¥ 7.03B¥ 7.94B¥ 10.68B¥ 8.05B¥ 6.19B
Total Assets¥ 16.16B¥ 16.24B¥ 16.46B¥ 11.83B¥ 8.95B
Total Debt¥ 2.77B¥ 2.50B¥ 1.86B¥ 1.21B¥ 970.85M
Net Debt¥ -4.26B¥ -5.44B¥ -8.83B¥ -6.84B¥ -5.22B
Total Liabilities-----
Stockholders Equity¥ 9.59B¥ 10.33B¥ 11.91B¥ 8.78B¥ 6.40B
Cash Flow-
Free Cash Flow-----
Operating Cash Flow-----
Investing Cash Flow-----
Financing Cash Flow-----
Currency in CNY

Innovent Biologics Earnings and Revenue History

Innovent Biologics Debt to Assets

Innovent Biologics Cash Flow

Innovent Biologics Forecast EPS vs Actual EPS

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis